Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Go back to Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 215.50 -3.55 (1.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $219.05 | 52 Week High | $333.65 | |||
| Open | $219.05 | 52 Week Low | $223.02 | |||
| Day High | $220.17 | P/E | 27.59 | |||
| Day Low | $215.26 | EPS | $7.81 | |||
| Volume | 2,635,886 | |||||
| (NASDAQ: STOK) | Delayed: 28.43 -0.5 (1.73%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.93 | 52 Week High | $ | |||
| Open | $28.85 | 52 Week Low | $ | |||
| Day High | $28.91 | P/E | N/A | |||
| Day Low | $28.01 | EPS | $ | |||
| Volume | 1,560,349 | |||||
